Apogee Therapeutics (APGE) Total Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Current Liabilities data on file, last reported at $33.0 million in Q1 2026.

• Quarterly Total Current Liabilities changed 0.02% year-over-year to $33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.0 million (changed 0.02% YoY) and the FY2025 annual result came in at $27.9 million, down 2.29% from the prior year.
• Total Current Liabilities advanced to $33.0 million in Q1 2026 per APGE's latest filing, from $27.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $34.0 million in Q3 2025 and bottomed at $10.0 million in Q4 2022.
• The 5-year median for Total Current Liabilities is $27.9 million (2025), against an average of $25.5 million.
• The widest annual swing landed in 2023, when Total Current Liabilities surged 105.99%; it then declined 2.29% in 2025.
• Tracing APGE's Total Current Liabilities over 5 years: stood at $10.0 million in 2022, then surged by 105.99% to $20.6 million in 2023, then soared by 38.92% to $28.6 million in 2024, then declined by 2.29% to $27.9 million in 2025, then rose by 18.08% to $33.0 million in 2026.
• Per Business Quant, the three latest APGE Total Current Liabilities figures stand at $33.0 million (Q1 2026), $27.9 million (Q4 2025), and $34.0 million (Q3 2025).

Peer Comparison